Bacchus Therapeutics

Bacchus Therapeutics is a biotech company that exploits cancer’s hypermetabolic state by targeting specific cancer metabolic pathways. We identified a novel pathway to target that is synthetic lethal to the cancer-causing gene, MYC. Our drug is translatable to all MYC-driven cancers, which encompass about 50-70% of all cancers.